Added to YB: 2026-05-21
Pitch date: 2026-05-18
GRCE [bullish]
Grace Therapeutics, Inc.
+1.87%
current return
Author Info
Triple S is a professional special situations investor who shares ideas in their newsletter. Sign up for the newsletter.
Company Info
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
Market Cap
$33.6M
Pitch Price
$2.14
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.33
P/E
-5.68
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Stock Trade Compilation Episode Siete - Grace Therapeutics, Inc.
GRCE: GTx-104 CRL cited CMC/manufacturing issues, NOT clinical efficacy concerns—key difference. IV reformulation of approved drug for superior delivery. Management confident issues addressable via Type A meeting. Stock -50% on headline overreaction. CMC fixes = solvable vs years of trials. Positioned via options.
Read full article (1 min)